Response to: Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update" by Braun
et al
Ann Rheum Dis
.
2023 Sep;82(9):e206.
doi: 10.1136/ard-2023-223937.
Epub 2023 Mar 6.
Authors
Sofia Ramiro
1
2
,
Elena Nikiphorou
3
4
5
,
Alexandre Sepriano
6
,
Augusta Ortolan
7
8
,
Casper Webers
9
10
,
Xenofon Baraliakos
11
,
Robert Bm Landewé
2
12
,
Désirée van der Heijde
3
Affiliations
1
Rheumatology, Leiden University Medical Center, Leiden, The Netherlands sofiaramiro@gmail.com.
2
Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands.
3
Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
4
King's College Hospital, London, UK.
5
Centre for Rheumatic Diseases, King's College London, London, UK.
6
Leiden Universitair Medisch Centrum, Leiden, The Netherlands.
7
Department of Medicine DIMED, University of Padova, Rheumatology Unit, Padua, Italy.
8
Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy.
9
Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands.
10
Maastricht University, Maastricht, The Netherlands.
11
Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany.
12
Rheumatology & Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
PMID:
36878690
DOI:
10.1136/ard-2023-223937
No abstract available
Keywords:
Biological Therapy; Epidemiology; Spondylitis, Ankylosing.
Publication types
Comment
MeSH terms
Axial Spondyloarthritis*
Humans
Spondylarthritis* / drug therapy
Spondylitis, Ankylosing*